Europe stocks set to fall with traders cautious on possible coronavirus treatment

  • 📰 CNBC
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 72%

Belgique Nouvelles Nouvelles

Belgique Dernières Nouvelles,Belgique Actualités

European stocks were set to fall on Friday morning as traders looked ahead to fresh economic data and digested a report that raised doubts over a possible coronavirus treatment.

The U.K.'s FTSE 100 was set to slide by 73 points, the German DAX by 230 points and the French CAC 40 by 92 points, according to IG Markets.

Risk sentiment took a hit late on Thursday after a report in the Financial Times, citing documents accidentally published by the WHO, said that drug remdesivir from Gilead had failed to improve patients' conditions. Gilead noted that study was "terminated early due to low enrollment," leaving it "underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive."

Earnings on Friday come from the likes of Sanofi, Nestle and Signify. Retail sales for the U.K. will be released at 7 a.m. London time and a central bank decision in Russia is set for later in the morning.

 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

May we suggest a retraction as again NO ONE publishes phase 1 trials and/or “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation”.

University of Chicago are participating in two Phase 3 clinical trials conducted by Gilead; 113 of them have severe forms of the disease. A physician said when some people start taking the drug, fevers come down and some come off ventilators. Explain CNBC

Here you go. “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation,” a University of Chicago spokesperson said

Here I fact check for you. Seeing you don’t know first thing about journalism. Misinforming public. Pointdexter, no one bases squat on phase 1 trials. Gilead already on Phase 3 trials genius with recovery in MOST SEVERE CASES. Care to explain your source?

Perhaps you should fact check your sources . It’s what we call Journalism 101. Explain. Remdesivir, a Gilead Sciences antiviral drug, is reportedly showing promise for patients participating in two Gilead clinical trials involving 2,400 severe cases.

Best to fact check CNBC before running a story that had no basis in truth. NOBODY bases anything on Phase 1 trials. 😂👌🏻 Phase 3 is what Gilead is doing now pointdexter with 3600 patients in the trial. Run that propaganda for the White House family who has no shares in Gilead.

Japan To block acquisition of foreign capital such as Avegan

We have AVIGAN Don't lose hope United States is strong

Please keep telling us what to think.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 12. in BE

Belgique Dernières Nouvelles, Belgique Actualités